A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group

In 1994, approximately 34,000 to 43,000 Americans will be diagnosed with small cell lung cancer, and 60% to 70% of these individuals will have extensive-stage disease. The median survival time of patients with extensive-stage small cell lung cancer is 8 to 10 months and 10% or less will survive 2 ye...

Full description

Saved in:
Bibliographic Details
Published inSeminars in oncology Vol. 22; no. 3 Suppl 6; p. 75
Main Authors Jett, J R, Kirschling, R J, Jung, S H, Marks, R S
Format Journal Article
LanguageEnglish
Published United States 01.06.1995
Subjects
Carcinoma, Small Cell - drug therapy
Female
Granulocyte Colony-Stimulating Factor - therapeutic use
Humans
Lung Neoplasms - drug therapy
Male
Paclitaxel - adverse effects
Paclitaxel - therapeutic use
Remission Induction
Online AccessGet more information

Cover

More Information
Summary:In 1994, approximately 34,000 to 43,000 Americans will be diagnosed with small cell lung cancer, and 60% to 70% of these individuals will have extensive-stage disease. The median survival time of patients with extensive-stage small cell lung cancer is 8 to 10 months and 10% or less will survive 2 years. There have been no major advances in the treatment of this stage of disease in the past decade. Phase II trials with promising new single-agent chemotherapeutic drugs are justifiable. We report the design and toxicity of a phase II trial with single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in previously untreated patients with extensive-stage small cell lung cancer.
ISSN:0093-7754